Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

#What Are the Projected Market Size and Growth Rates for the VariZIG Market From 2025 To 2029?#_x000D_

In the past few years, the Varizig market size has exhibited an XX (HCAGR). It is anticipated to expand from a value of $XX million in 2024 to $XX million in 2025, growing at a compound annual growth rate (CAGR) of XX%. Its growth within the historical timeframe can be attributed to various factors such as growth in healthcare spending, increase in organ transplant procedures, more government funding for immunization initiatives, an expanding geriatric population, and boost in private insurance coverage._x000D_

_x000D_

Predictions for the Varizig market size estimated an impressive XX% FCAGR in the forthcoming years, culminating in a value of $XX million by 2029, with a compound annual growth rate (CAGR) of XX%. This projected increase during the forecast period can be linked to a number of factors such as the growing cases of chickenpox, escalating investments in varicella-related biologics, amplified demand for immune globulin products and an increase in public health initiatives as well as in clinical trials. The major trends projected for the forecast period include technological advancements, global humanitarian adoption, breakthroughs in recombinant DNA technology, the creation of innovative formulations, and the rise of telemedicine._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20448&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the VariZIG Market?#_x000D_

The uptick in varicella-zoster virus infections is presumed to propel the varizig market. This highly contagious virus, known as the varicella-zoster virus (VZV), is responsible for causing chickenpox in its primary infection stage and can be reactivated later to result in shingles (herpes zoster). A reduced rate of vaccinations, a growing elderly population, and immune suppression due to certain medical therapies are causing an escalating incidence of varicella-zoster virus (VZV) infections, leading to conditions such as chickenpox and shingles. Varizig provides varicella-zoster virus sufferers with passive immunity, helps reduce the severity and span of chickenpox symptoms, thwarts future complications in high-risk groups like immune-deficient patients, and safeguards against severe consequences in newborns and pregnant women exposed to the virus. As an illustration, the Florida Department of Health, a US National Agency, confirmed in November 2024 that the count of varicella cases rose to 653 in 2023, a significant increase from 428 cases in 2022. Consequently, the escalating occurrence of varicella-zoster virus infections is fueling the varizig market._x000D_

_x000D_

#Which Primary Segments of the VariZIG Market Are Driving Growth and Industry Transformations?#_x000D_

The varizig market covered in this report is segmented –_x000D_

_x000D_

1) By Patient Condition: Immunocompromised Patients; Pregnant Women_x000D_

2) By Distribution Channel: Hospitals; Pharmacies; Healthcare Providers_x000D_

3) By End User: Adult; Geriatric; Pediatric_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20448&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the VariZIG Market?#_x000D_

North America was the largest region in the varizig market in 2024. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Technological Trends Are Reshaping the VariZIG Industry Dynamics?#_x000D_

The primary trend in the varizig market involves negotiating supply contracts to cater to high-risk patient groups, widening distribution networks, and satisfying the growing need for passive immunization, particularly in emergency and high-risk situations. Supply agreements are legal agreements between entities that stipulate the stipulations for delivering goods or services, encompassing pricing, delivery timeframes, and the responsibilities of each party. For example, Kamada Ltd., a biopharmaceutical firm from Israel, declared a procurement agreement worth $11.4 million in July 2022 to supply its product VARIZIG to a confidential international association predominantly working in Latin America. The supply is anticipated to occur from the final quarter of 2022 through the first half of 2023. This agreement manifests Kamada’s initiative to broaden its sales of FDA-endorsed plasma-derived therapies in international markets, underlining the commercial promise beyond North America. VARIZIG is specifically recommended for post-exposure prophylaxis of varicella (chickenpox) in at-risk groups, like immunocompromised patients and newborns, making it an essential treatment option for these groups._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/varizig-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the VariZIG Market?#_x000D_

VariZIG is a hyperimmune globulin derived from human plasma with high antibodies against the varicella-zoster virus (VZV). It is used as a post-exposure prophylaxis to reduce the severity of chickenpox in high-risk individuals, such as immunocompromised patients, pregnant women, and newborns. Administered intramuscularly, it provides passive immunity by delivering pre-formed antibodies. Varizig is most effective when given within 96 hours of VZV exposure._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20448_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model